Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Market watchers are predicting strong performance driven by the strong demand of Lilly's blockbuster treatments, particularly its insulin portfolio. However, there are also concerns about tirzepatide … Read More